期刊文献+

注射用化疗药物用药调查分析 被引量:5

Drug investigation analysis of chemotherapeutic drugs for injection
原文传递
导出
摘要 目的:对首都医科大学附属北京天坛医院(以下简称我院)注射用化疗药物使用情况进行点评,以提高化疗药物临床应用的合理性及安全性。方法:由我院信息中心导出2016年1月至2017年11月使用注射用化疗药物的患者用药医嘱,通过我院HIS系统,统计化疗患者的一般资料、诊断、使用的化疗方案及其剂量、溶媒、药物浓度、给药次序、给药速度及辅助化疗药物的使用情况等。结果:我院2016年1月至2017年11月间使用注射用化疗药物的患者共992例,共计9744条医嘱。不合理医嘱533条(5.5%),涉及患者121例(12.2%)。涉及不合理医嘱最多的前3位药物分别为依托泊苷注射液(459条,86.1%)、注射用奈达铂(28条,5.3%)、注射用培美曲塞二钠(25条,4.7%)。不合理医嘱中出现的用药差错主要为溶媒选用不当(481条,90.2%)以及诊断与用药不符(25条,4.7%)。结论:我院注射用化疗药物使用情况基本合理,但有些方面仍需进一步改进以保证患者的用药安全。 Objective:This study was designed to evaluate the use of chemotherapeutic drugs for injection in Beijing Tiantan Hospital(hereinafter referred to as our hospital) and improve the rationality and safety of chemotherapeutic drugs.Methods:The information of chemotherapeutic drugs from January 2016 to November 2017 was imported from our information center.Our HIS system was used to calculated the general information,diagnosis,chemotherapy used,dosage,vehicle,drug concentration,drug sequence,administration speed,and use of adjuvant chemotherapeutic drugs of chemotherapy patients.Results:From January 2016 to November 2017,there were 992 patients receiving chemotherapeutic drugs for injection in our hospital with totaled 9744 medical orders.Top three drugs involved in the problems were etoposide(459 pieces,86.1 %),nedaplatin(28 pieces,5.3%),and pemetrexed disodium(25 pieces,4.7%).The medication errors were mainly due to the wrong choice of solvents(481 pieces,90.2%) and discrepancies between diagnosis and medication(25 pieces,4.7%).Conclusion:The use of chemotherapeutic drugs for injection in our hospital is basically reasonable,but some aspects still need further improvement to ensure the safety of patients’ medication.
作者 叶佳丹 余克富 赵志刚 YE Jia-dan;YU Ke-fu;ZHAO Zhi-gang(Department of Pharmacy,Bejig Tian Tan Hopital,Capital Medical Uniersity,Bejing 100050,China)
出处 《临床药物治疗杂志》 2019年第12期70-73,共4页 Clinical Medication Journal
关键词 化疗药物 用药调查 合理性 安全性 chemotherapeutic drugs drug investigation rationality safety
  • 相关文献

参考文献3

二级参考文献27

  • 1曾万勇,周际昌,王奇璐,孙燕,苏嵋,冯奉仪,王金万.不同剂量顺铂为主的联合方案治疗恶性肿瘤的疗效及肾毒性[J].实用癌症杂志,1993,8(3):137-139. 被引量:15
  • 2秦相义,李彦君.介绍一种肿瘤化疗防吐仪[J].中华护理杂志,2005,40(7):548-548. 被引量:2
  • 3周际昌 冯秦仪 等.高剂量顺铂为主联合化疗对恶性肿瘤的治疗评价[J].中华肿瘤杂志,1987,9(2):136-136.
  • 4FertéC,Paci A,Zizi M,et al.Natural history,management and pharmacokinetics of everolimus-induced-oral ulcers insights into compliance issues[J].Eur J Cancer,2011,47(15):2249-2255.
  • 5Ai D,Banchs J,Owusu-Agyemang P,et al.Chemotherapyinduced cardiovascular toxicity:beyond anthracyclines[J].Minerva Anestesiol,2014,80(5):586-594.
  • 6PopelováO,Sterba M,HaskováP,et al.Dexrazoxaneafforded protection against chronic anthracycline cardiotoxicity in vivo:effective rescue of cardiomyocytes from apoptotic cell death[J].Br J Cancer,2009,101(5):792-802.
  • 7Bria E,Cuppone F,Milella M,et al.Trastuzumab cardiotoxicity:biological hypotheses and clinical open issues[J].Expert Opin Biol Ther,2008,8(12):1963-1971.
  • 8Humphreys BD,Atkins MB.Rapid development of hypertension by sorafenib:toxicity or target?[J].Clin Cancer Res,2009,15(19):5947-5949.
  • 9Maitland ML,Kasza KE,Karrison T,et al.Ambulatory monitoring detects sorafenib induced blood pressure elevations on the first day of treatment[J].Clin Cancer Res,2009,15(19):6250-6257.
  • 10Petrini I,lencioni M,Ricasoli M,et al.PhaseⅡtrial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma[J].Cancer Chemother Pharmacol,2012,69(3):773-780.

共引文献27

同被引文献55

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部